MY188689A - Gene therapy composition - Google Patents
Gene therapy compositionInfo
- Publication number
- MY188689A MY188689A MYPI2018701967A MYPI2018701967A MY188689A MY 188689 A MY188689 A MY 188689A MY PI2018701967 A MYPI2018701967 A MY PI2018701967A MY PI2018701967 A MYPI2018701967 A MY PI2018701967A MY 188689 A MY188689 A MY 188689A
- Authority
- MY
- Malaysia
- Prior art keywords
- genes
- gene therapy
- apoptosis
- therapy composition
- inducing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Problem: To provide a gene therapy composition, which gene therapy composition promotes cancer cell apoptosis by delivering apoptosis-inducing genes comprising a combination of multiple genes into cancer cells, and to a liposome vector for transferring the gene therapy composition to cancer cells and a method of preparing the liposome vector. Solution: A gene therapy composition comprising a gene therapy composition for preventing and/or treating cancer whose anti-tumor genes are apoptosis-inducing genes, wherein the apoptosis-inducing genes comprise p53 genes, FUS-1 genes, TRAIL genes and IL-24 genes. composition for preventing and/or treating cancer whose anti-tumor genesare apoptosis-inducing genes, wherein the apoptosis-inducing genes comprise p53 genes, FUS-1 genes, TRAIL genes and IL-24 genes. (Figure 1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2015/005342 WO2017068614A1 (en) | 2015-10-23 | 2015-10-23 | Gene therapy composition |
Publications (1)
Publication Number | Publication Date |
---|---|
MY188689A true MY188689A (en) | 2021-12-23 |
Family
ID=58557009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2018701967A MY188689A (en) | 2015-10-23 | 2015-10-23 | Gene therapy composition |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP6837984B2 (en) |
MY (1) | MY188689A (en) |
SG (1) | SG11201803940PA (en) |
WO (1) | WO2017068614A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102631802B1 (en) | 2018-09-05 | 2024-01-31 | 엘지전자 주식회사 | Method for encoding/decoding video signal, and apparatus therefor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002506651A (en) * | 1998-03-16 | 2002-03-05 | イントロジェン・セラピューティクス,インコーポレイテッド | Multi-gene vector |
-
2015
- 2015-10-23 SG SG11201803940PA patent/SG11201803940PA/en unknown
- 2015-10-23 MY MYPI2018701967A patent/MY188689A/en unknown
- 2015-10-23 WO PCT/JP2015/005342 patent/WO2017068614A1/en active Application Filing
- 2015-10-23 JP JP2017546280A patent/JP6837984B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2017068614A1 (en) | 2017-04-27 |
JPWO2017068614A1 (en) | 2018-08-09 |
SG11201803940PA (en) | 2018-06-28 |
JP6837984B2 (en) | 2021-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1252351A1 (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
EP3411079A4 (en) | Engineered mammalian cells for cancer therapy | |
GB2557123A (en) | Modified cells and methods of therapy | |
EP3370743A4 (en) | Methods for preparing cells for adoptive t cell therapy | |
MX2018001776A (en) | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation. | |
MX2018004263A (en) | Multiplexed genome editing. | |
MX2018005377A (en) | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use. | |
EP3260539A4 (en) | Method for transferring cas9 mrna into mammalian fertilized egg by electroporation | |
WO2016012544A3 (en) | Enhanced reprogramming to ips cells | |
MX2017014163A (en) | K-ras modulators. | |
MX2022012013A (en) | Compositions and methods for tumor transduction. | |
EP3554557A4 (en) | Methods of treating cells containing fusion genes by genomic targeting | |
SG11201912631PA (en) | Aav9-mediated gene therapy for treating mucopolysaccharidosis type i | |
MX368442B (en) | Fusion protein inhibiting angiogenesis or growth and use thereof. | |
EP3207377A4 (en) | Circulating tumor cell diagnostics for therapy targeting pd-l1 | |
MX2019010039A (en) | Compositions and methods for tumor transduction. | |
PH12017500370A1 (en) | Compound targeting il-23a and tnf-alpha and uses thereof | |
EP3342858A4 (en) | Ror1-positive mesenchymal stem cells and method for preparing same, pharmaceutical composition containing ror1-positive mesenchymal stem cells and method for preparing same, and method for preventing or treating diseases by using ror1-positive mesenchymal stem cells | |
SG11202002457RA (en) | Gene therapy for treating mucopolysaccharidosis type ii | |
EP3717653A4 (en) | Gene therapy for mucopolysaccharidosis iiia | |
EP3998341A3 (en) | Adenoviral vectors | |
IL267057A (en) | Gene therapy for mucopolysaccharidosis, type i | |
NZ726050A (en) | Modulators of androgen synthesis | |
MX2018006527A (en) | Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer. | |
MX2018012872A (en) | Compositions and methods for enhanced gene expression of pklr. |